Chimeric antigen receptor T-cell data from Bluebird Bio Inc. (and partner Celgene Corp.) stole the show recently at the American Society of Hematology (ASH) meeting, but the firm's results in sickle cell disease (SCD) may get more attention as time goes on. Not much is heard about the indication overall, CEO Nick Leschly acknowledged.